Review
Oncology
Qingyi Wang, Xiaoling Feng, Xiaofang Liu, Siyu Zhu
Summary: According to the meta-analysis, higher pretreatment serum CA-125 levels are associated with poor prognosis in epithelial ovarian cancer (EOC) patients.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Juhun Lee, Jong Mi Kim, Yoon Hee Lee, Gun Oh Chong, Dae Gy Hong
Summary: This study analyzed the relationship between serum CA-125 levels after chemotherapy and clinical outcomes in Korean women with epithelial ovarian cancer. The results showed that serum CA-125 is correlated with clinical outcomes and can be used to predict platinum resistance in ovarian cancer treatment.
ANTICANCER RESEARCH
(2022)
Article
Oncology
Christoph Wohlmuth, Vladimir Djedovic, Susanne K. Kjaer, Allan Jensen, Rosalind Glasspool, Patricia Roxburgh, Anna DeFazio, Sharon E. Johnatty, Penelope M. Webb, Francesmary Modugno, Diether Lambrechts, Joellen M. Schildkraut, Andrew Berchuck, Liv Cecilie Vestrheim Thomsen, Line Bjorge, Estrid Hogdall, Claus K. Hogdall, Ellen L. Goode, Stacey J. Winham, Keitaro Matsuo, Beth Y. Karlan, Jenny Lester, Marc T. Goodman, Pamela J. Thompson, Tanja Pejovic, Marjorie J. Riggan, Katherine Lajkosz, Alicia Tone, Taymaa May
Summary: This study analyzed data from 176 women with low-grade serous ovarian cancer through a multi-center collaborative effort, revealing that elevated post-treatment CA-125 levels are significantly associated with poor survival, while FIGO staging and residual disease also impact patient outcomes.
Article
Multidisciplinary Sciences
Szymon Piatek, Grzegorz Panek, Zbigniew Lewandowski, Dominika Piatek, Przemyslaw Kosinski, Mariusz Bidzinski
Summary: The nadir CA-125 level in patients with epithelial ovarian cancer is associated with progression-free survival but not overall survival. Patients with nadir CA-125 levels between 11-35 U/ml after first-line treatment have a higher risk of recurrence compared to patients with levels <= 10 U/ml.
SCIENTIFIC REPORTS
(2021)
Review
Chemistry, Analytical
Mehrab Pourmadadi, Ali Moammeri, Amin Shamsabadipour, Yasamin Farahanian Moghaddam, Abbas Rahdar, Sadanand Pandey
Summary: Diagnosing early-stage cancers is crucial for saving lives and reducing mortality rates. Detection of the cancer antigen CA-125 is a key step in the treatment of certain cancers, such as ovarian cancer. This review discusses various optical and electrochemical methods for detecting CA-125, compares their performance and sensitivity, investigates commercial detection kits, and evaluates their applicability and accuracy.
Article
Chemistry, Multidisciplinary
Julian Matthias Metzler, Daniel Fink, Patrick Imesch
Summary: Ibrutinib, a small-molecule inhibitor of Bruton's tyrosine kinase, is used to treat hematological diseases like chronic lymphocytic leukemia. The hypothesis that it may suppress the tumor marker CA-125 in ovarian cancer is based on an observation in a patient with low-grade serous ovarian cancer who received ibrutinib for CLL. A mechanistic model explaining this potential drug effect is proposed for further research.
APPLIED SCIENCES-BASEL
(2021)
Article
Biochemistry & Molecular Biology
Nattinee Krathumkhet, Toyoko Imae, Fu-ming Wang, Chiou-Chung Yuan, Jusni Manidae Lumban Gaol, Nophawan Paradee
Summary: In this study, a novel cancer antigen 125 (CA125) biomarker detection method based on electro-chemical immunosensor was demonstrated. The biomarker on conductive composite materials of carbon ink/carbon dot/zinc oxide (C-ink/CD/ZnO) was used as an electrode platform, enhancing the interaction of antibodies (Ab) with the catalytic performance of ZnO. The created immunosensor showed a wide linear range and low detection limit, making it an accurate and efficient diagnostic tool for CA125 and other biomarkers in clinical sample analysis.
BIOELECTROCHEMISTRY
(2023)
Article
Oncology
Thomas J. Herzog, Sandro Pignata, Sharad A. Ghamande, Maria-Jesus Rubio, Keiichi Fujiwara, Christof Vulsteke, Deborah K. Armstrong, Jalid Sehouli, Robert L. Coleman, Hani Gabra, Giovanni Scambia, Bradley J. Monk, Jose A. Arranz, Kimio Ushijima, Rabbie Hanna, Claudio Zamagni, Robert M. Wenham, Antionio Gonzalez-Martin, Brian Slomovitz, Yan Jia, Lisa Ramsay, Krishnansu S. Tewari, Susan C. Weil, Ignace B. Vergote
Summary: The study aimed to determine the efficacy of farletuzumab, an antifolate receptor-alpha monoclonal antibody, in improving progression-free survival (PFS) in patients with platinum-sensitive recurrent ovarian cancer. The results showed that adding farletuzumab did not improve PFS, and the expression of the folate receptor-alpha was not measured in this study.
GYNECOLOGIC ONCOLOGY
(2023)
Article
Multidisciplinary Sciences
Syamel Muhammad, Reyhan Julio Azwan, Rauza Sukma Rita, Restu Susanti, Yusrawati
Summary: This study investigates the predictive role of IL6, CA-125, and HE4 in tumor resectability in pre-operative patients with advanced epithelial ovarian cancer and finds a correlation between these markers and tumor resectability.
Review
Biochemistry & Molecular Biology
Nicole E. James, Morgan Woodman, Jennifer R. Ribeiro
Summary: EOC patients have low response rates to immunotherapies, but evidence suggests ovarian tumors are immunogenic and immune-related genomic profiles can serve as prognostic markers. Specific research areas that need to be addressed include developing immune-based prognostic signatures and driving advancements in this field.
Article
Medicine, General & Internal
Olivier Colomban, Elizabeth M. Swisher, Rebecca Kristeleit, Iain McNeish, Ronnie Shapira-Frommer, Sandra Goble, Kevin K. Lin, Lara Maloney, Gilles Freyer, Benoit You
Summary: Mathematical modeling of early CA-125 kinetics can be used as an indicator of rucaparib efficacy in recurrent ovarian carcinoma patients. The KELIM-PARP score is associated with treatment response and progression-free survival. This study suggests the potential use of this strategy in selecting patients for PARPi-based treatment regimens.
Article
Oncology
Koceila Amroun, Raphael Chaltiel, Fabien Reyal, Reza Kianmanesh, Aude-Marie Savoye, Marine Perrier, Zoubir Djerada, Olivier Bouche
Summary: Using a joint model (JM) of longitudinal CA-125 level during neoadjuvant chemotherapy (NAC) is a reliable predictor of complete interval cytoreductive surgery (ICRS) feasibility in patients with advanced ovarian cancer (AOC), helping to avoid unnecessary laparotomy.
Article
Oncology
Er Yue, Guangchao Yang, Yuanfei Yao, Guangyu Wang, Atish Mohanty, Fang Fan, Ling Zhao, Yanqiao Zhang, Tamara Mirzapoiazova, Tonya C. Walser, Lorna Rodriguez-Rodriguez, Yuman Fong, Ravi Salgia, Edward Wenge Wang
Summary: Ovarian cancer is a deadly disease with urgent need for new treatments. The development of a conditionally replicative oncolytic adenovirus (CRAd) that targets MUC16/CA-125 in cancer cells shows promising anti-cancer effects. This approach represents a unique and practical direction for further investigation in ovarian cancer treatment.
Article
Biochemical Research Methods
Jin Song, Lori J. J. Sokoll, Zhen Zhang, Daniel W. W. Chan
Summary: Close to 75% of ovarian cancer cases are diagnosed at an advanced stage, with a high rate of relapse after primary therapy. Therefore, it is crucial to identify strategies for early detection of ovarian cancer recurrence to improve outcomes.
CLINICAL PROTEOMICS
(2023)
Article
Immunology
Lingeng Lu, Wenxue Ma, Caroline H. Johnson, Sajid A. Khan, Melinda L. Irwin, Lajos Pusztai
Summary: Somatic mutation-derived neoantigens are used to develop an mRNA vaccine targeting CA-125 neoantigen for breast and ovarian cancer. Immuno-bioinformatics tools were used to predict CD8' T cell epitopes and a self-adjuvant mRNA vaccine was constructed to enhance cross-presentation by dendritic cells. Immune responses post-immunization were estimated using an in silico algorithm, showing IFN-c and CD8' T cell response. The strategy described in this study can be used to design precision multi-epitope mRNA vaccines targeting multiple neoantigens.
Article
Oncology
Rachel G. Woodford, Deborah D. X. Zhou, Peey-Sei Kok, Sally J. Lord, Michael Friedlander, Ian C. Marschner, R. John Simes, Chee Khoon Lee
Summary: Overall survival (OS) is the gold standard endpoint for oncology trials, but progression-free survival 2 (PFS-2) has been proposed as a surrogate endpoint due to delays in OS data maturation. A meta-analysis found that PFS-2 had a moderate correlation with OS across diverse tumors and therapies, performing consistently better than PFS-1 and objective response rate (ORR). PFS-2 should be included as a key endpoint in future randomized trials of solid tumors.
Article
Health Policy & Services
Karina Dahl Steffensen
Summary: Person-centred care and shared decision-making are part of national clinical standards in Australia's healthcare sector. However, challenges remain in implementing and measuring these standards, as well as training healthcare professionals. Consumer involvement in health research, policy, and clinical service governance is increasing, and there is a focus on encouraging patients to ask questions and improving consumer health literacy.
ZEITSCHRIFT FUR EVIDENZ FORTBILDUNG UND QUALITAET IM GESUNDHEITSWESEN
(2022)
Article
Medicine, General & Internal
Marina Fabbi, Delfina Costa, Daniela Russo, Laura Arenare, Gabriele Gaggero, Simona Signoriello, Giovanni Scambia, Carmela Pisano, Nicoletta Colombo, Nunzia Simona Losito, Gilberto Filaci, Anna Spina, Daniela Califano, Giosue Scognamiglio, Angiolo Gadducci, Delia Mezzanzanica, Marina Bagnoli, Silvano Ferrini, Vincenzo Canzonieri, Paolo Chiodini, Francesco Perrone, Sandro Pignata
Summary: By investigating the expression of ADAM17 in ovarian cancer tissues, this study aimed to identify prognostic factors for advanced ovarian cancer patients undergoing first-line therapy. The results showed that high expression of ADAM17 was associated with worse prognosis, especially in patients with no residual disease at baseline.
Article
Oncology
Ursula A. A. Matulonis, Domenica Lorusso, Ana Oaknin, Sandro Pignata, Andrew Dean, Hannelore Denys, Nicoletta Colombo, Toon Van Gorp, Jason A. A. Konner, Margarita Romeo Marin, Philipp Harter, Conleth G. G. Murphy, Jiuzhou Wang, Elizabeth Noble, Brooke Esteves, Michael Method, Robert L. L. Coleman
Summary: The MIRV antibody-drug conjugate demonstrated significant antitumor activity and favorable tolerability in patients with platinum-resistant epithelial ovarian cancer, particularly in those who had received multiple prior therapies including bevacizumab.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Anesthesiology
Christina Mortensen, Karina Dahl Steffensen, Emma Simonsen, Kamille Herskind, Jonna Skov Madsen, Dorte Aalund Olsen, Ditte Bork Iversen, Troels Korshoj Bergmann, Anton Pottegard, Tore Bjerregaard Stage
Summary: Using a translational approach, this study assessed the utility of neurofilament light chain (NFL) as a biomarker for paclitaxel-induced peripheral neuropathy (PIPN) in a human cell model and in ovarian cancer patients, finding that high serum NFL levels predicted adverse outcomes related to PIPN.
Article
Multidisciplinary Sciences
Karina Dahl Steffensen, Dorte Gilsa Hansen, Kurt Espersen, Susanne Lauth, Peter Fosgrau, Anders Meinert Pedersen, Peter Sigerseth Groen, Christian Sauvr, Karina Olling
Summary: This paper describes the development of a model called SDM:HOSP, which aims to achieve lasting shared decision making (SDM) between patients and healthcare professionals. Through four phases of development, including the development of conceptual elements, field testing, evaluation, and the development of the final model, SDM:HOSP can be easily adapted to different organizations and cultures.
Review
Biology
Amelia Barcellini, Alexandra Charalampopoulou, Loris De Cecco, Andrei Fodor, Emanuela Rabaiotti, Giorgio Candotti, Simona Secondino, Angelica Facoetti, Laura Deborah Locati, Sandro Pignata, Ester Orlandi, Giorgia Mangili
Summary: Radiotherapy is increasingly being used in combination with surgery, chemotherapy, and novel drugs to treat ovarian cancer. This review aims to summarize the current understanding of the radiosensitivity and radioresistance of ovarian cancer, which is the deadliest gynecological cancer worldwide. Understanding the mechanisms of radiosensitivity and identifying potential biomarkers of radioresistance could be crucial in guiding clinical decision-making, considering the high rate of recurrence in and out of the radiotherapy fields, especially in the era of personalized oncology.
Article
Oncology
Alicja Puszkiel, Benoit You, Lea Payen, Jonathan Lopez, Jerome Guitton, Pascal Rousset, Juliette Fontaine, Julien Peron, Denis Maillet, Sophie Tartas, Nathalie Bonnin, Veronique Trillet-Lenoir, Olivier Colomban, Diane Augu-Denechere, Gilles Freyer, Michel Tod
Summary: The objective of this study was to develop a pharmacokinetic-pharmacodynamic (PK-PD) model linking everolimus and sorafenib exposure with biomarker dynamics and progression-free survival (PFS). The study found a correlation between sorafenib plasma exposure and soluble vascular endothelial growth factor receptor 2 (sVEGFR2) dynamics. The simulated dosing schedule of sorafenib 200 mg bid 5 days-on/2 days-off + continuous everolimus 5 mg qd showed a higher median PFS compared to the EVESOR trial.
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2023)
Article
Oncology
Domenica Lorusso, Nicoletta Colombo, Antonio Casado Herraez, Alessandro D. Santin, Emeline Colomba, David Scott Miller, Keiichi Fujiwara, Sandro Pignata, Sally E. Baron-Hay, Isabelle Laure Ray-Coquard, Ronnie Shapira-Frommer, Yong Man Kim, Mary Mccormack, Rachid Massaad, Allison Martin Nguyen, Qi Zhao, Jodi Mckenzie, Vimalanand S. Prabhu, Vicky Makker
Summary: In the phase 3 study 309/KEYNOTE-775, Lenvatinib and pembrolizumab (LEN+PEMBRO) showed significant improvements in efficacy compared to treatment of physician's choice (TPC) for patients with advanced endometrial cancer (aEC). Health-related quality of life (HRQoL) was reported.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Medicine, General & Internal
Olivier Colomban, Elizabeth M. Swisher, Rebecca Kristeleit, Iain McNeish, Ronnie Shapira-Frommer, Sandra Goble, Kevin K. Lin, Lara Maloney, Gilles Freyer, Benoit You
Summary: Mathematical modeling of early CA-125 kinetics can be used as an indicator of rucaparib efficacy in recurrent ovarian carcinoma patients. The KELIM-PARP score is associated with treatment response and progression-free survival. This study suggests the potential use of this strategy in selecting patients for PARPi-based treatment regimens.
Review
Oncology
Giuseppe Caruso, Amelia Barcellini, Roberta Mazzeo, Roberta Gallo, Maria Giuseppa Vitale, Anna Passarelli, Giorgia Mangili, Sandro Pignata, Innocenza Palaia
Summary: Vulvar Paget's disease (VPD) is a rare form of cutaneous adenocarcinoma of the vulva, often misdiagnosed due to non-specific symptoms. This systematic review aims to provide a concise overview of the current evidence and emerging therapeutic opportunities for VPD.
Article
Oncology
Valentina Tuninetti, Eleonora Ghisoni, Sandro Pignata, Elisa Picardo, Francesco Raspagliesi, Claudia Andreetta, Elena Maldi, Grazia Artioli, Serafina Mammoliti, Lucia Zanchi, Angelica Sikokis, Nicoletta Biglia, Alessandro Parisi, Vincenzo Dario Mandato, Claudia Carella, Gennaro Cormio, Marco Marinaccio, Andrea Puppo, Biagio Paolini, Lucia Borsotti, Giulia Scotto, Margherita Turinetto, Dario Sangiolo, Massimo Di Maio, Giorgio Valabrega
Summary: The expression of Ki67 at diagnosis does not predict the response to PARP inhibitors in BRCA wild-type ovarian cancer patients.
Letter
Hematology
Faheem Farooq, Justin S. Brandt, Elyce Cardonick, Evgeniya Polushkina, Julie Vose, Sairah Ahmed, Praveen Ramakrishnan Geethakumari, Adam J. Olszewski, Hesham Yasin, Umar Farooq, Nada Hamad, Yong Lin, Charlotte Maggen, Robert Fruscio, Mina Mhallem Gziri, Karina Dahl Steffensen, Frederic Amant, Andrew M. Evens
Article
Oncology
Antony J. Mersiades, Benjamin J. Solomon, David M. Thomas, Chee K. Lee, Michelle M. Cummins, Lucille Sebastian, Mandy L. Ballinger, Emily Collignon, Olivia M. H. Turnbull, Sonia Yip, Rachael L. Morton, Chris Brown, Patrick J. Wheeler, Malinda Itchins, R. John Simes, Nick Pavlakis
Summary: The ASPiRATION study is a national prospective observational cohort study conducted in Australia that aims to assess the feasibility, clinical value, and economic value of comprehensive genomic profiling (CGP) in newly diagnosed metastatic non-squamous non-small-cell lung cancer. The study will enroll 1000 participants and collect clinical outcome data for a minimum of 2 years. The outcomes of the study will describe the ability of CGP to identify actionable genomic alterations, leading to personalized treatment recommendations, and evaluate the feasibility, cost, and utility of implementing CGP nationally. The study is important in advancing the understanding and application of CGP in lung cancer diagnosis and treatment in Australia.
Review
Oncology
Kara K. Palmer, Adam Pennell, Bryan Terlizzi, Michael A. Nunu, David F. Stodden, Leah E. Robinson, Alice Bergamini, Sandro Pignata, Ester Orlandi, Giorgia Mangili, David A. Gewirtz
Summary: The management of high-risk gestational trophoblastic neoplasia requires a multimodality treatment that may include radiotherapy. There is little consensus on the indication and role of radiotherapy for extra-central nervous system localizations. Radiotherapy can have a hemostatic role, but the high rate of necrosis requires attention to fractionation schedules and radiation type.
